Cargando…
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration
The Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) were developed to address widespread deficiencies in the reporting of such studies. The REMARK checklist consists of 20 items to report for published tumor marker prognostic studies. A detailed paper was published explaining...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093349/ https://www.ncbi.nlm.nih.gov/pubmed/29873743 http://dx.doi.org/10.1093/jnci/djy088 |
_version_ | 1783347678759878656 |
---|---|
author | Sauerbrei, Willi Taube, Sheila E McShane, Lisa M Cavenagh, Margaret M Altman, Douglas G |
author_facet | Sauerbrei, Willi Taube, Sheila E McShane, Lisa M Cavenagh, Margaret M Altman, Douglas G |
author_sort | Sauerbrei, Willi |
collection | PubMed |
description | The Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) were developed to address widespread deficiencies in the reporting of such studies. The REMARK checklist consists of 20 items to report for published tumor marker prognostic studies. A detailed paper was published explaining the rationale behind checklist items, providing positive examples and giving empirical evidence of the quality of reporting. REMARK provides a comprehensive overview to educate on good reporting and provide a valuable reference for the many issues to consider when designing, conducting, and analyzing tumor marker studies and prognostic studies in medicine in general. Despite support for REMARK from major cancer journals, prognostic factor research studies remain poorly reported. To encourage dissemination and uptake of REMARK, we have produced this considerably abridged version of the detailed explanatory manuscript, which may also serve as a brief guide to key issues for investigators planning tumor marker prognostic studies. To summarize the current situation, more recent papers investigating the quality of reporting and related reporting guidelines are cited, but otherwise the literature is not updated. Another important impetus for this paper is that it serves as a basis for literal translations into other languages. Translations will help to bring key information to a larger audience world-wide. Many more details can be found in the original paper. |
format | Online Article Text |
id | pubmed-6093349 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-60933492018-08-22 Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration Sauerbrei, Willi Taube, Sheila E McShane, Lisa M Cavenagh, Margaret M Altman, Douglas G J Natl Cancer Inst Commentary The Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) were developed to address widespread deficiencies in the reporting of such studies. The REMARK checklist consists of 20 items to report for published tumor marker prognostic studies. A detailed paper was published explaining the rationale behind checklist items, providing positive examples and giving empirical evidence of the quality of reporting. REMARK provides a comprehensive overview to educate on good reporting and provide a valuable reference for the many issues to consider when designing, conducting, and analyzing tumor marker studies and prognostic studies in medicine in general. Despite support for REMARK from major cancer journals, prognostic factor research studies remain poorly reported. To encourage dissemination and uptake of REMARK, we have produced this considerably abridged version of the detailed explanatory manuscript, which may also serve as a brief guide to key issues for investigators planning tumor marker prognostic studies. To summarize the current situation, more recent papers investigating the quality of reporting and related reporting guidelines are cited, but otherwise the literature is not updated. Another important impetus for this paper is that it serves as a basis for literal translations into other languages. Translations will help to bring key information to a larger audience world-wide. Many more details can be found in the original paper. Oxford University Press 2018-06-04 /pmc/articles/PMC6093349/ /pubmed/29873743 http://dx.doi.org/10.1093/jnci/djy088 Text en © The Author(s) 2018. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Commentary Sauerbrei, Willi Taube, Sheila E McShane, Lisa M Cavenagh, Margaret M Altman, Douglas G Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration |
title | Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An
Abridged Explanation and Elaboration |
title_full | Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An
Abridged Explanation and Elaboration |
title_fullStr | Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An
Abridged Explanation and Elaboration |
title_full_unstemmed | Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An
Abridged Explanation and Elaboration |
title_short | Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An
Abridged Explanation and Elaboration |
title_sort | reporting recommendations for tumor marker prognostic studies (remark): an
abridged explanation and elaboration |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093349/ https://www.ncbi.nlm.nih.gov/pubmed/29873743 http://dx.doi.org/10.1093/jnci/djy088 |
work_keys_str_mv | AT sauerbreiwilli reportingrecommendationsfortumormarkerprognosticstudiesremarkanabridgedexplanationandelaboration AT taubesheilae reportingrecommendationsfortumormarkerprognosticstudiesremarkanabridgedexplanationandelaboration AT mcshanelisam reportingrecommendationsfortumormarkerprognosticstudiesremarkanabridgedexplanationandelaboration AT cavenaghmargaretm reportingrecommendationsfortumormarkerprognosticstudiesremarkanabridgedexplanationandelaboration AT altmandouglasg reportingrecommendationsfortumormarkerprognosticstudiesremarkanabridgedexplanationandelaboration |